Picropodophyllin

Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

Product Specifications

CAS Number

[477-47-4]

Product Name Alternative

AXL1717; Picropodophyllotoxin; PPP

UNSPSC

12352005

Hazard Statement

H301, H312, H315, H319, H335

Target

Apoptosis; IGF-1R

Type

Natural Products

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/AXL1717.html

Purity

99.85

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1OC[C@]2([H])[C@@H](O)C3=C(C=C4OCOC4=C3)[C@@H](C5=CC(OC)=C(OC)C(OC)=C5)[C@@]21[H]

Molecular Formula

C22H22O8

Molecular Weight

414.41

Precautions

H301, H312, H315, H319, H335

References & Citations

[1]Girnita A, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004 Jan 1;64 (1) :236-42.|[2]Menu E, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006 Jan 15;107 (2) :655-60. Epub 2005 Jul 26.|[3]Bieghs L, et al. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget. 2014 Nov 30;5 (22) :11193-208.|[4]Tomizawa M, et al. Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncol Lett. 2014 Nov;8 (5) :2023-2026. Epub 2014 Aug 27.|[5]Stromberg T, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006 Jan 15;107 (2) :669-78. Epub 2005 Sep 15.|[6]Kong YL, et al. Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway. Acta Pharmacol Sin. 2016 Feb;37 (2) :217-27.